Literature DB >> 19627868

Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.

J D England1, G S Gronseth, G Franklin, G T Carter, L J Kinsella, J A Cohen, A K Asbury, K Szigeti, J R Lupski, N Latov, R A Lewis, P A Low, M A Fisher, D Herrmann, J F Howard, G Lauria, R G Miller, M Polydefkis, A J Sumner.   

Abstract

BACKGROUND: Distal symmetric polyneuropathy (DSP) is the most common variety of neuropathy. Since the evaluation of this disorder is not standardized, the available literature was reviewed to provide evidence-based guidelines regarding the role of autonomic testing, nerve biopsy and skin biopsy for the assessment of polyneuropathy.
METHODS: A literature review using MEDLINE, EMBASE, Science Citation Index and Current Contents was performed to identify the best evidence regarding the evaluation of polyneuropathy published between 1980 and March 2007. Articles were classified according to a four-tiered level of evidence scheme and recommendations were based upon the level of evidence. RESULTS AND
CONCLUSIONS: 1. Autonomic testing may be considered in the evaluation of patients with polyneuropathy to document autonomic nervous system dysfunction (Level B). Such testing should be considered especially for the evaluation of suspected autonomic neuropathy (Level B) and distal small fiber sensory polyneuropathy (SFSN) (Level C). A battery of validated tests is recommended to achieve the highest diagnostic accuracy (Level B). 2. Nerve biopsy is generally accepted as useful in the evaluation of certain neuropathies as in patients with suspected amyloid neuropathy, mononeuropathy multiplex due to vasculitis, or with atypical forms of chronic inflammatory demyelinating polyneuropathy (CIDP). However, the literature is insufficient to provide a recommendation regarding when a nerve biopsy may be useful in the evaluation of DSP (Level U). 3. Skin biopsy is a validated technique for determining intraepidermal nerve fiber (IENF) density and may be considered for the diagnosis of DSP, particularly SFSN (Level C). There is a need for additional prospective studies to define more exact guidelines for the evaluation of polyneuropathy.

Entities:  

Mesh:

Year:  2009        PMID: 19627868     DOI: 10.1016/j.pmrj.2008.11.011

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  13 in total

1.  Prognostic Value of Heart Rate Variability in Patients With Cancer.

Authors:  Ying Guo; Shalini Koshy; David Hui; J Lynn Palmer; Ki Shin; Mehtap Bozkurt; Syed Wamique Yusuf
Journal:  J Clin Neurophysiol       Date:  2015-12       Impact factor: 2.177

2.  Validation of the composite autonomic symptom scale 31 (COMPASS-31) in patients with and without small fiber polyneuropathy.

Authors:  R Treister; K O'Neil; H M Downs; A L Oaklander
Journal:  Eur J Neurol       Date:  2015-04-23       Impact factor: 6.089

3.  Initial Development and Validation of a Patient-Reported Symptom Survey for Small-Fiber Polyneuropathy.

Authors:  Roi Treister; Mette Lodahl; Magdalena Lang; Shelley S Tworoger; Shlomo Sawilowsky; Anne Louise Oaklander
Journal:  J Pain       Date:  2017-01-04       Impact factor: 5.820

4.  Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.

Authors:  Todd Hulgan; Rebecca T Levinson; Mariana Gerschenson; Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarm; Tanate Jadwattanakul; Daniel E LiButti; Heidi Fink; Justin C McArthur; Gigi J Ebenezer; Peter Hauer; Deborah Murdock; Cecilia M Shikuma; David C Samuels
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

Review 5.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

6.  Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy.

Authors:  Krish Chandrasekaran; Mohammad Salimian; Sruthi R Konduru; Joungil Choi; Pranith Kumar; Aaron Long; Nina Klimova; Cheng-Ying Ho; Tibor Kristian; James W Russell
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

7.  Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.

Authors:  Jemily Malvar; Florin Vaida; Chelsea Fitzsimons Sanders; J Hampton Atkinson; William Bohannon; John Keltner; Jessica Robinson-Papp; David M Simpson; Christina M Marra; David B Clifford; Benjamin Gelman; Juanjuan Fan; Igor Grant; Ronald J Ellis
Journal:  Pain       Date:  2015-04       Impact factor: 7.926

8.  Natural history and biomarkers in hereditary sensory neuropathy type 1.

Authors:  Vera Fridman; Anne Louise Oaklander; William S David; Elise A Johnson; Jessica Pan; Peter Novak; Robert H Brown; Florian S Eichler
Journal:  Muscle Nerve       Date:  2015-02-11       Impact factor: 3.217

Review 9.  Updates in diabetic peripheral neuropathy.

Authors:  Kelsey Juster-Switlyk; A Gordon Smith
Journal:  F1000Res       Date:  2016-04-25

10.  Automated PGP9.5 immunofluorescence staining: a valuable tool in the assessment of small fiber neuropathy?

Authors:  Nathalie Van Acker; Michael Ragé; Ellen Sluydts; Michiel W M Knaapen; Martine De Bie; Maarten Timmers; Erik Fransen; Carla Duymelinck; Stefanie De Schepper; Praveen Anand; Theo Meert; Léon Plaghki; Patrick Cras
Journal:  BMC Res Notes       Date:  2016-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.